Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Purchases 72,700 Shares of Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA – Get Free Report) CEO Vlad Vitoc purchased 72,700 shares of the stock in a transaction dated Monday, June 1st. The stock was acquired at an average price of $1.39 per share, for a total transaction of $101,053.00. Following the completion of the transaction, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at approximately $1,356,808.19. The trade was a 8.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

MAIA Biotechnology Price Performance

Shares of MAIA opened at $1.30 on Tuesday. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $3.19. The stock has a market cap of $79.04 million, a price-to-earnings ratio of -1.94 and a beta of 0.23. The firm has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $1.52.

Get MAIA Biotechnology alerts:

MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. On average, equities analysts expect that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of MAIA Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new position in MAIA Biotechnology in the 2nd quarter valued at about $29,000. Ritholtz Wealth Management acquired a new position in shares of MAIA Biotechnology in the fourth quarter valued at approximately $35,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $52,000. Corsair Capital Management L.P. acquired a new stake in MAIA Biotechnology during the first quarter worth approximately $140,000. Finally, Geode Capital Management LLC boosted its position in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares during the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

(Get Free Report)

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

Featured Stories

• Five stocks we like better than MAIA Biotechnology
• 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait
• Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?
• Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors
• Why 1 Little-Known ETF Is Riding the AI Chip Shortage

Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.